Manufacturers report positive results for tislelizumab in phase III trial for Lung Cancer

Manufacturers report that tislelizumab, a checkpoint inhibitor under investigation, demonstrated a significant improvement in progression free survival in non-squamous non-small cell lung cancer vs pemetrexed and platinum chemotherapy alone at the interim analysis.

Biospace Inc.